Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vascular endothelial growth factor gene therapy - HSCI

Drug Profile

Vascular endothelial growth factor gene therapy - HSCI

Alternative Names: Neovasculgen; PI-VEGF165; VEGF gene therapy - HSCI

Latest Information Update: 28 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Human Stem Cells Institute
  • Class Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial disorders
  • No development reported Diabetic foot ulcer

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-foot-ulcer in Russia (IM, Injection)
  • 01 Aug 2015 Clinical trials in Diabetic foot ulcer in Russia (IM)
  • 05 Feb 2015 Human Stem Cell Institute plans a phase I/II trial for Peripheral nerve injuries (Adjuvant therapy) in Russia (NCT02352649)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top